Seif Al-Abri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Seif Al-Abri has a total of 555 co-authors. Here are the top co-authors by number of shared publications:
- Adil Al Wahaibi
Ministry of Health, Muscat, Oman
21 shared publications - Amal Al Maani
Center for Disease Control and Prevention, Ministry of Health, Muscat, Oman
20 shared publications - Eskild Petersen
Department of Science and Environment, PandemiXcenter, Roskilde University, Roskilde, Denmark
13 shared publications - Amina Al-Jardani
Central Public Health Laboratories, Center for Disease Control and Prevention, Ministry of Health, Muscat, Oman, Oman
11 shared publications Bader Al-Rawahi
Affiliation Department of Communicable diseases, Ministry of Health, Centre for disease control and prevention, Muscat, Oman
10 shared publications- Alimuddin Zumla
Center for Clinical Microbiology, Institute of Infection, Immunity and Transplantation, University College London, London, UK; NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK
9 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 173
Childhood vaccination at a crossroads: rebuilding confidence, overcoming inequities, and translating scientific advances into global health gains
- 5 November 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 173
Open AccessChildhood vaccination at a crossroads: rebuilding confidence, overcoming inequities, and translating scientific advances into global health gains
- Open Access
- 19 September 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 172
From pandemic preparedness commitments to demonstrable capability: priorities for the 2026 United Nations High-Level Meeting
- 19 September 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 172
Open AccessFrom pandemic preparedness commitments to demonstrable capability: priorities for the 2026 United Nations High-Level Meeting
- Open Access
- 5 August 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 171
From Evidence to Impact: A New Chapter for IJID
- 5 August 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 171
Open AccessFrom Evidence to Impact: A New Chapter for IJID
- Open Access
- 4 August 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 171
Meningococcal B vaccination for gonorrhoea prevention in men who have sex with men – time to revisit the recommendation?
- 4 August 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 171
Open AccessMeningococcal B vaccination for gonorrhoea prevention in men who have sex with men – time to revisit the recommendation?
- Open Access
- 22 July 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 171, 108994
The Silent Aftershock: Preventing Tuberculosis Transmission and Treatment Interruption in Venezuela’s Post-Earthquake Shelters
- 22 July 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 171, 108994
Open AccessThe Silent Aftershock: Preventing Tuberculosis Transmission and Treatment Interruption in Venezuela’s Post-Earthquake Shelters
- 24 June 2026
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 33 (6)
The PHEIC Threshold: What Ebola Has That Hantavirus Does Not
- 24 June 2026
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 33 (6)
The PHEIC Threshold: What Ebola Has That Hantavirus Does Not
- 17 June 2026
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 33 (6)
The Cycle of Recurrence: Why Ebola Persists in an Era of Countermeasure Abundance
Abundant medical countermeasures, including highly efficacious strain-specific vaccines, have not stopped Ebola from returning. Each outbreak exposes the same fatal weakness: global health governance still reacts faster than it builds. Audits after the fact change little without sustained domestic financing, empowered frontline systems, and political accountability that survives the news cycle. The cycle can break—but only if Ebola control pivots from episodic emergency response to resilient, sovereign, operationally agile preparedness.
- 17 June 2026
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 33 (6)
The Cycle of Recurrence: Why Ebola Persists in an Era of Countermeasure Abundance
Abundant medical countermeasures, including highly efficacious strain-specific vaccines, have not stopped Ebola from returning. Each outbreak exposes the same fatal weakness: global health governance still reacts faster than it builds. Audits after the fact change little without sustained domestic financing, empowered frontline systems, and political accountability that survives the news cycle. The cycle can break—but only if Ebola control pivots from episodic emergency response to resilient, sovereign, operationally agile preparedness.
- Open Access
Genomic Characterization and Predictors of Mortality in Invasive Streptococcus pneumoniae Disease in Oman: A Four-Year National Genomic Study
Background/Objectives: Following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in Oman, this study aimed to characterize the genomic epidemiology, serotype distribution, and antimicrobial resistance (AMR) of Streptococcus pneumoniae causing invasive pneumococcal disease (IPD). Methods: All IPD isolates collected through national laboratory-based surveillance between 2018 and 2021 were analyzed using Whole-Genome Sequencing (WGS). Bioinformatics tools determined serotypes, multilocus sequence types (MLSTs), and Global Pneumococcal Sequence Clusters (GPSCs). Clinical correlates and predictors of mortality were assessed via multivariate logistic regression. Results: A total of 129 IPD isolates were included. Serotype 3 (11.6%) was the most prevalent, followed by 23B and 9N (10.8% each), and 8 (8.5%). PCV13 serotypes accounted for only 26.4% of isolates, while PCV20 coverage reached 59.7%. Significant clonal diversity was observed, with GPSC12 (Serotype 3) and GPSC699 (Serotype 9N/13) being prominent lineages. Multidrug resistance (MDR) was identified in 36.4% of isolates, primarily driven by GPSC6 and GPSC699. The case fatality rate was 23.0%. Advanced age (≥65 years) and clinical presentation with bacteremia were significant independent predictors of death, whereas bacterial genotype and AMR status were not. Conclusions: The findings demonstrate significant serotype replacement in Oman after the introduction of PCV13. The high prevalence of non-vaccine serotypes and emerging MDR clones justifies the transition to higher-valency vaccines like PCV20. Sustained genomic surveillance remains essential to monitor the evolving landscape of invasive pneumococcal lineages.
Open AccessGenomic Characterization and Predictors of Mortality in Invasive Streptococcus pneumoniae Disease in Oman: A Four-Year National Genomic Study
Background/Objectives: Following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in Oman, this study aimed to characterize the genomic epidemiology, serotype distribution, and antimicrobial resistance (AMR) of Streptococcus pneumoniae causing invasive pneumococcal disease (IPD). Methods: All IPD isolates collected through national laboratory-based surveillance between 2018 and 2021 were analyzed using Whole-Genome Sequencing (WGS). Bioinformatics tools determined serotypes, multilocus sequence types (MLSTs), and Global Pneumococcal Sequence Clusters (GPSCs). Clinical correlates and predictors of mortality were assessed via multivariate logistic regression. Results: A total of 129 IPD isolates were included. Serotype 3 (11.6%) was the most prevalent, followed by 23B and 9N (10.8% each), and 8 (8.5%). PCV13 serotypes accounted for only 26.4% of isolates, while PCV20 coverage reached 59.7%. Significant clonal diversity was observed, with GPSC12 (Serotype 3) and GPSC699 (Serotype 9N/13) being prominent lineages. Multidrug resistance (MDR) was identified in 36.4% of isolates, primarily driven by GPSC6 and GPSC699. The case fatality rate was 23.0%. Advanced age (≥65 years) and clinical presentation with bacteremia were significant independent predictors of death, whereas bacterial genotype and AMR status were not. Conclusions: The findings demonstrate significant serotype replacement in Oman after the introduction of PCV13. The high prevalence of non-vaccine serotypes and emerging MDR clones justifies the transition to higher-valency vaccines like PCV20. Sustained genomic surveillance remains essential to monitor the evolving landscape of invasive pneumococcal lineages.
- Open Access
- 29 May 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 170, 108838
Outbreak at Sea: The MV Hondius Hantavirus Cluster as a Sentinel for Global Pandemic Readiness
- 29 May 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 170, 108838
Open AccessOutbreak at Sea: The MV Hondius Hantavirus Cluster as a Sentinel for Global Pandemic Readiness
- Top Cited PapersOpen Access
- 12 February 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 165, 108472
“Things Fall Apart”: The Unravelling of Global Health Governance and the Imperative for Action Preserving Infectious Disease Prevention and Control
- 12 February 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 165, 108472
Top Cited PapersOpen Access“Things Fall Apart”: The Unravelling of Global Health Governance and the Imperative for Action Preserving Infectious Disease Prevention and Control